{"entity":{"type":"insider","cik":"0001597407","url":"/insider/0001597407","json_url":"/insider/0001597407.json","name":"Clayman Michael D.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":17,"first":"2016-05-17","last":"2020-05-27","span_basis":"filed_date"},"name_variants":[{"name":"Clayman Michael D.","source":"filing","n_filings":17,"first_seen":"2016-05-17","last_seen":"2020-05-27"}],"transactions":[{"id":2966008,"accession":"0001209191-20-032287","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-032287","line_url":"/filing/0001209191-20-032287#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10256.0,"shares_display":"10,256","price_per_share":9.75,"price_display":"9.75","price_state":"stated","total_value":99996.0,"total_display":"99,996.00","total_whole":"99,996","shares_owned_after":346605.0,"shares_owned_after_display":"346,605","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-26","filed_date":"2020-05-27","scope":"insider"},{"id":8027660,"accession":"0001209191-19-045123","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-045123","line_url":"/filing/0001209191-19-045123#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2317.0,"shares_display":"2,317","price_per_share":10.8486,"price_display":"10.85","price_state":"stated","total_value":25136.2062,"total_display":"25,136.21","total_whole":"25,136","shares_owned_after":72249.0,"shares_owned_after_display":"72,249","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-08","filed_date":"2019-08-08","scope":"insider"},{"id":7871213,"accession":"0001209191-19-029182","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-029182","line_url":"/filing/0001209191-19-029182#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4012.0,"shares_display":"4,012","price_per_share":12.4794,"price_display":"12.48","price_state":"stated","total_value":50067.3528,"total_display":"50,067.35","total_whole":"50,067","shares_owned_after":74868.0,"shares_owned_after_display":"74,868","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-10","filed_date":"2019-05-13","scope":"insider"},{"id":8118286,"accession":"0001209191-19-019135","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-019135","line_url":"/filing/0001209191-19-019135#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4046.0,"shares_display":"4,046","price_per_share":12.36,"price_display":"12.36","price_state":"stated","total_value":50008.56,"total_display":"50,008.56","total_whole":"50,009","shares_owned_after":70856.0,"shares_owned_after_display":"70,856","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-12","filed_date":"2019-03-13","scope":"insider"},{"id":8150782,"accession":"0001209191-19-002065","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-002065","line_url":"/filing/0001209191-19-002065#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3278.0,"shares_display":"3,278","price_per_share":12.36,"price_display":"12.36","price_state":"stated","total_value":40516.08,"total_display":"40,516.08","total_whole":"40,516","shares_owned_after":66810.0,"shares_owned_after_display":"66,810","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-03","filed_date":"2019-01-04","scope":"insider"},{"id":6426941,"accession":"0001209191-18-058086","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-18-058086","line_url":"/filing/0001209191-18-058086#line-7","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":17.0953,"price_display":"17.10","price_state":"stated","total_value":85476.5,"total_display":"85,476.50","total_whole":"85,477","shares_owned_after":69166.0,"shares_owned_after_display":"69,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-09","filed_date":"2018-11-13","scope":"insider"},{"id":6101849,"accession":"0001209191-18-046129","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-046129","line_url":"/filing/0001209191-18-046129#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":22.33,"price_display":"22.33","price_state":"stated","total_value":223300.0,"total_display":"223,300.00","total_whole":"223,300","shares_owned_after":75282.0,"shares_owned_after_display":"75,282","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-08-09","filed_date":"2018-08-10","scope":"insider"},{"id":5182486,"accession":"0001209191-17-059880","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-059880","line_url":"/filing/0001209191-17-059880#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":23.6,"price_display":"23.60","price_state":"stated","total_value":118000.0,"total_display":"118,000.00","total_whole":"118,000","shares_owned_after":35395.0,"shares_owned_after_display":"35,395","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-08","filed_date":"2017-11-09","scope":"insider"},{"id":4358316,"accession":"0001209191-17-038221","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-038221","line_url":"/filing/0001209191-17-038221#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":17.2303,"price_display":"17.23","price_state":"stated","total_value":86151.5,"total_display":"86,151.50","total_whole":"86,152","shares_owned_after":20146.0,"shares_owned_after_display":"20,146","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-06-05","filed_date":"2017-06-06","scope":"insider"},{"id":2890616,"accession":"0001209191-16-152006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-152006","line_url":"/filing/0001209191-16-152006#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1667.0,"shares_display":"1,667","price_per_share":18.4093,"price_display":"18.41","price_state":"stated","total_value":30688.3031,"total_display":"30,688.30","total_whole":"30,688","shares_owned_after":30721.0,"shares_owned_after_display":"30,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-23","filed_date":"2016-11-23","scope":"insider"},{"id":2747119,"accession":"0001209191-16-151827","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-151827","line_url":"/filing/0001209191-16-151827#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1666.0,"shares_display":"1,666","price_per_share":17.9473,"price_display":"17.95","price_state":"stated","total_value":29900.2018,"total_display":"29,900.20","total_whole":"29,900","shares_owned_after":29054.0,"shares_owned_after_display":"29,054","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-22","filed_date":"2016-11-23","scope":"insider"},{"id":2256886,"accession":"0001209191-16-151664","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-151664","line_url":"/filing/0001209191-16-151664#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1666.0,"shares_display":"1,666","price_per_share":17.9036,"price_display":"17.90","price_state":"stated","total_value":29827.3976,"total_display":"29,827.40","total_whole":"29,827","shares_owned_after":27388.0,"shares_owned_after_display":"27,388","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-21","filed_date":"2016-11-22","scope":"insider"},{"id":3255616,"accession":"0001209191-16-122560","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-122560","line_url":"/filing/0001209191-16-122560#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":10.4052,"price_display":"10.41","price_state":"stated","total_value":20810.4,"total_display":"20,810.40","total_whole":"20,810","shares_owned_after":13568.0,"shares_owned_after_display":"13,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-20","filed_date":"2016-05-23","scope":"insider"},{"id":2249059,"accession":"0001209191-16-122295","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-122295","line_url":"/filing/0001209191-16-122295#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":9.6486,"price_display":"9.65","price_state":"stated","total_value":19297.2,"total_display":"19,297.20","total_whole":"19,297","shares_owned_after":11568.0,"shares_owned_after_display":"11,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-19","filed_date":"2016-05-20","scope":"insider"},{"id":2054442,"accession":"0001209191-16-121790","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-121790","line_url":"/filing/0001209191-16-121790#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":10.2325,"price_display":"10.23","price_state":"stated","total_value":20465.0,"total_display":"20,465.00","total_whole":"20,465","shares_owned_after":9568.0,"shares_owned_after_display":"9,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-18","filed_date":"2016-05-19","scope":"insider"},{"id":2282712,"accession":"0001209191-16-121361","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-121361","line_url":"/filing/0001209191-16-121361#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":9.7325,"price_display":"9.73","price_state":"stated","total_value":19465.0,"total_display":"19,465.00","total_whole":"19,465","shares_owned_after":7568.0,"shares_owned_after_display":"7,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-17","filed_date":"2016-05-18","scope":"insider"},{"id":2178819,"accession":"0001209191-16-120983","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-120983","line_url":"/filing/0001209191-16-120983#line-1","is_derivative":false,"issuer_cik":"0001419600","issuer_name":"Flexion Therapeutics Inc","issuer_ticker":"FLXN","issuer_name_source":null,"issuer_url":"/issuer/0001419600","owner_cik":"0001597407","owner_name":"Clayman Michael D.","owner_display_name":"Clayman Michael D.","owner_url":"/insider/0001597407","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":9.5125,"price_display":"9.51","price_state":"stated","total_value":19025.0,"total_display":"19,025.00","total_whole":"19,025","shares_owned_after":5568.0,"shares_owned_after_display":"5,568","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-05-16","filed_date":"2016-05-17","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":16,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001419600","name":"Flexion Therapeutics Inc","url":"/issuer/0001419600","role":"Director, Officer (President and CEO)","n_filings":17,"first_seen":"2016-05-17","last_seen":"2020-05-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001597407","retrieved_at":"2026-08-24T23:16:10+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}